Therapeutic Potential of 3D ‐Printed Nifurtimox for Chagas Disease: Effects on Survival, Parasitemia Control and Immune Modulation
Tropical Medicine & International Health · 2026
DOI: 10.1111/tmi.70085 ↗Kurz gefasst
Fachartikel in der Zeitschrift Tropical Medicine & International Health, 2026. Verfasst von Tatiana Prata Menezes und 11 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Immunobiology of Inflammation, Department of Biological Science, Federal University of Ouro Preto, Ouro Preto, Minas Gerais, Brazil. Hauptthemen laut MEDLINE: Chagas Disease, Nifurtimox, Trypanocidal Agents, Parasitemia. Die Arbeit nennt 41 Literaturangaben. Gefördert von: National Council for Scientific and Technological Development (CNPq), CNPq and DECIT/SECTICS/Ministry of Health, Foundation for Research Support of the State of Minas Gerais (FAPEMIG).
Abstract (Originalsprache)
Objective
The Trypanosoma cruzi immunopathology is sustained by a progressive inflammatory process triggered by parasite antigens, resulting in structural and functional changes in infected organs. Current etiological treatments of benznidazole and nifurtimox show limited efficacy and high toxicity, particularly during chronic infection stages. To address these limitations, a novel 3D printing formulation was applied to nifurtimox (3D nifurtimox) to improve its dissolution and reduce cytotoxicity. This study evaluated the therapeutic efficacy of 3D nifurtimox in experimental T. cruzi infection.
Methods
Female Swiss mice were infected with 4 × 10 3 trypomastigotes of T. cruzi (Y strain) and treated orally for 28 days with nifurtimox (conventional or 3D) at doses of 25, 50 or 100 mg/kg or benznidazole 100 mg/kg. Survival rates, parasitemia and inflammatory profiles in cardiac and skeletal muscles were assessed through quantification of cytokines TNF, IL‐6, CCL2 and IL‐10.
Results
3D nifurtimox at 50 and 100 mg/kg showed more efficacy in controlling blood parasites in mice surviving and regulating inflammatory cytokine patterns in cardiac and skeletal muscle tissues than conventional nifurtimox. In addition, 3D nifurtimox 100 mg/kg demonstrated complete parasite clearance and sustained protection even under immunosuppression. The improved efficacy is likely related to enhanced dissolution and bioavailability afforded by the 3D printing process, which transformed nifurtimox into an amorphous solid state.
Conclusion
3D nifurtimox represents a promising new version of nifurtimox capable of being used in low doses with comparable or superior effects to benznidazole (100 mg/kg) and can be considered a promising tool for anti‐ T. cruzi therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Immunobiology of Inflammation, Department of Biological Science, Federal University of Ouro Preto, Ouro Preto, Minas Gerais, Brazil.
- Graduate Program in Health and Nutrition, Federal University of Ouro Preto, Ouro Preto, Minas Gerais, Brazil.
- Graduate Program in Health Sciences, Infectiology and Tropical Medicine, Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil.
- Laboratory of Food, Drug, and Cosmetics, School of Health Sciences, University of Brasilia, Brasília, Distrito Federal, Brazil.
- Faculty of Biochemical and Pharmaceutical Sciences, National University of Rosario, Rosario, Argentina.
ORCID-Profile: Tatiana Prata Menezes, Sirlaine Pio, Ana Luiza Lima, Bianca Alves Almeida Machado, Giselle Bedogni, Idejan Padilha Gross, Claudio J Salomon, Marcilio Cunha-Filho
Förderung
- National Council for Scientific and Technological Development (CNPq)
- CNPq and DECIT/SECTICS/Ministry of Health
- Foundation for Research Support of the State of Minas Gerais (FAPEMIG)
- Funding Authority for Studies and Projects (FINEP)
- National Scientific and Technical Research Council (CONICET)
- Conselho Nacional de Desenvolvimento Científico e Tecnológico
- Fundação de Amparo à Pesquisa do Estado de Minas Gerais
- Financiadora de Estudos e Projetos
Zitieren
APA
Menezes, T. P., Louise, V., Pio, S., Souza, D. M. S., Lima, A. L., Oliveira, D. M., Machado, B. A. A., Bedogni, G., Gross, I. P., Salomon, C. J., Cunha-Filho, M., & Talvani, A. (2026). Therapeutic Potential of 3D ‐Printed Nifurtimox for Chagas Disease: Effects on Survival, Parasitemia Control and Immune Modulation. Tropical Medicine & International Health. https://doi.org/10.1111/tmi.70085
Vancouver
Menezes TP, Louise V, Pio S, Souza DMS, Lima AL, Oliveira DM, et al. Therapeutic Potential of 3D ‐Printed Nifurtimox for Chagas Disease: Effects on Survival, Parasitemia Control and Immune Modulation. Tropical Medicine & International Health. 2026. doi:10.1111/tmi.70085
BibTeX
@article{Menezes2026,
author = {Menezes, Tatiana Prata and Louise, Vitória and Pio, Sirlaine and Souza, Débora Maria Soares and Lima, Ana Luiza and Oliveira, Daniel Malta and Machado, Bianca Alves Almeida and Bedogni, Giselle and Gross, Idejan Padilha and Salomon, Claudio J and Cunha-Filho, Marcilio and Talvani, André},
title = {Therapeutic Potential of 3D ‐Printed Nifurtimox for Chagas Disease: Effects on Survival, Parasitemia Control and Immune Modulation},
journal = {Tropical Medicine & International Health},
year = {2026},
doi = {10.1111/tmi.70085}
}
EUVIMED